Large B-cell lymphoma-<i>IRF4</i>+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm?
Minke H. W. Huibers, Oussama Abla, Mara Andrés, Olga Balagué, Auke Beishuizen, Elisa Carraro, Aks Chiang, Monika Csóka, Bianca-Andreea David, Maëlle de Ville de Goyet, Gil Gilad, Daiki Hori, Rishi S. Kotecha, Edita Kabíčková, Wolfgang Hiddemann, Natasha Miakova, Véronique Minard‐Colin, Atsuko Nakazawa, Marta Pillon, Charlotte Rigaud, Itziar Salaverría, Ida Tölle, Jaime Verdú‐Amorós, Hannah von Mersi, Wilhelm Wössmann, Birgit Burkhardt, Andishe Attarbaschi
Abstract
Since 2022, large B-cell lymphoma with IRF4-rearrangment (LBCL-IRF4+) has been recognized as a definite entity by the World Health Organization (WHO) classification of hematolymphoid tumors. It is characterized by a follicular and/or diffuse growth pattern as well as a strong expression of IRF4, which is due to translocation of IRF4 with an immunoglobulin gene.Essential and desirable diagnostic criteria are set by the WHO, including clinical, morphological, immunophenotypical, and moleculargenetic parameters. [...]